NCT01496976 2025-12-19Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLLH. Lee Moffitt Cancer Center and Research InstitutePhase 2 Completed45 enrolled 12 charts